DMAA

Drugs Made in America Acquisition Corp. (DMAA) is exhibiting classic low-float SPAC dynamics following its recent extension vote, where $99M was redeemed. Despite this massive capital outflow, the stock has held steady above its $10.52 trust value, triggering ALPHA_MALE and PERFECT_STACK signals that indicate stealth accumulation. In the current RISK_ON regime where market internals show a healthy appetite for explosive beta, this institutional absorption of the remaining float sets the stage for a highly speculative breakout. The tight price action against a drastically shrinking float creates asymmetric upside as the market anticipates a target announcement before the new May 29 deadline.